

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 May 2024 (10.05.2024)



(10) International Publication Number
WO 2024/097846 A1

(51) International Patent Classification:

C07D 263/58 (2006.01) A61K 31/428 (2006.01)
C07D 277/82 (2006.01) A61P 7/02 (2006.01)
A61K 31/423 (2006.01)

(21) International Application Number:

PCT/US2023/078471

(22) International Filing Date:

02 November 2023 (02.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/382,032 02 November 2022 (02.11.2022) US

(71) Applicant: VERALOX THERAPEUTICS [US/US]; 321

Ballenger Center Drive, Suite 125, Frederick, Maryland
21703 (US).

(72) Inventors; and

(71) Applicants: MALONEY, David [US/US]; 1721 Canal
Clipper Court, Point of Rocks, Maryland 21777 (US).
FLANNER, Henry [US/US]; 19 Dellcastle Court, Mont-
gomery Village, Maryland 20886 (US). BOXER, Matthew
[US/US]; 6813 Rehnquist Ct., New Market, Maryland
21774 (US).

(74) Agent: SCHEIDEMAN, Matthew et al.; Cooley LLP ,

1299 Pennsylvania Avenue , Suite 700 , Washington, DC
20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

WO 2024/097846 A1

(54) Title: ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES

(57) Abstract: Provided are pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility for oral administration. Also provides are pharmaceutical formulations comprising selective 12-LOX inhibitors with high drug loading of 30% or more amorphously dispersed in selected from vinylpyrrolidone-vinyl acetate copolymers (Kollidon VA64), amino methacrylate copolymer (Eudragit EPO), Hydroxypropylmethylcellulose E3 (HPMC E3), or a combination thereof and make up 40 to 80% of the total solid content of the formulation. The formulation alternatively contains additives such as surfactants (sodium lauryl sulfate), crystal inhibitors, or pH modifiers up to 20% of the total solid content of the formulation.